Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.61 |
| ▸ | MAOA | P21397 | 9/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
| ▸ | TOP1 | P11387 | 1/20 | 0.50 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31683484 | 0.92 | MAOB (0.56) | MAOBMAOAHRH3CYP2D6NPC1 | |
| SCHEMBL31683615 | 0.90 | MAOB (0.56) | MAOBMAOAHRH3CYP2D6NPC1 | |
| SCHEMBL227895 | 0.85 | MAOB (0.61) | MAOBMAOAHRH3CYP2D6NPC1 | |
| SCHEMBL31683674 | 0.84 | MAOB (0.55) | MAOBMAOAHRH3CYP2D6NPC1 | |
| SCHEMBL4366122 | 0.83 | CYP24A1 (0.60) | MAOBALDH1A1SMN1; SMN2CYP24A1 | |
| SCHEMBL15874767 | 0.83 | CYP24A1 (0.60) | MAOBALDH1A1SMN1; SMN2CYP24A1 | |
| SCHEMBL8199928 | 0.82 | MAOB (0.55) | MAOBMAOAHRH3NPC1ALDH1A1 | |
| SCHEMBL8200931 | 0.81 | ITGB3 (0.58) | MAOBMAOAHRH3NPC1ALDH1A1 | |
| SCHEMBL29092251 | 0.80 | MAOB (0.58) | MAOBMAOAHRH3CYP2D6NPC1 | |
| SCHEMBL6491492 | 0.79 | ADRA1D (0.54) | MAOBMAOAHRH3CYP2D6ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | ESRRA, ESRRB, ESR2 | MAOB 958/4885MAOA 841/4885HRH3 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.